1. What Are Recombinant Proteins?

1.1 Recombinant Proteins Overview

1.2 History of Recombinant Proteins



2. Why There Exist Need for Recombinant Proteins?



3. Different Types of Recombinant DNA Technology



4. Mechanisms of Recombinant Protein Production

4.1 Recombinant Protein Production & Expression

4.2 Different Methods of Protein Production

4.3 Process for Producing Recombinant Proteins



5. Global Recombinant Therapeutic Proteins Market Overview

5.1 Current Market Scenario

5.2 Recombinant Proteins Clinical Pipeline Overview



6. Global Recombinant Therapeutic Proteins Market Dynamics

6.1 Market Drivers

6.2 Challenges



7. Recombinant Therapeutic Proteins Market Future Growth Outlook



8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country

8.1 Research till Registration

8.2 Marketed Recombinant Therapeutic Protein Drugs

8.3 Suspended & Discontinued Drugs in Clinical Pipeline



9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country

9.1 Research till Registration

9.2 Marketed Recombinant Erythropoietin Drugs

9.3 Suspended & Discontinued Drugs in Clinical Pipeline



10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country

10.1 Research till Registration

10.2 Marketed Recombinant Fusion Protein Drugs

10.3 Suspended & Discontinued Drugs in Clinical Pipeline



11. Competitive Landscape

11.1 Boehringer Ingelheim

11.2 Bristol-Myers Squibb

11.3 Celldex Therapeutics

11.4 Eli Liily

11.5 GlaxoSmithKline

11.6 Merck

11.7 Novartis

11.8 Regeneron Pharmaceuticals

11.9 Roche

11.10 Shire Pharmaceuticals

List of Figures

Figure 1-1: Most Commonly Used Recombinant Protein Products

Figure 1-2: Biopharmaceutical Approval in European Union & US During 2008-2013

Figure 3-1: Recombinant DNA Technologies

Figure 4-1: Process for Producing Recombinant Proteins

Figure 5-1: Global Biologics Market Classification



Figure 5-2: Global Protein Therapeutics Market (US$ Billion), 2013-2020

Figure 5-3: Global Therapeutic Protein Market by Region (%), 2014

Figure 5-4: Share of Producing Agents for Recombinant Proteins, 2014



Figure 5-5: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014

Figure 5-6: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014

Figure 5-7: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014

Figure 5-8: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014

Figure 5-9: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014

Figure 5-10: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014

Figure 5-11: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014

Figure 5-12: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014



Figure 5-13: Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014

Figure 5-14: Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014

Figure 5-15: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014

Figure 5-16: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014



Figure 5-17: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014

Figure 5-18: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014

Figure 5-19: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014

Figure 5-20: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014

Figure 5-21: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014

Figure 5-22: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014

List of Tables

Table 1-1: First Generation of Therapeutic Proteins

Table 1-2: Second Generation of Therapeutic Proteins

Table 1-3: Monoclonal Antibodies

Companies Mentioned

Boehringer Ingelheim,Bristol-Myers Squibb, Celldex Therapeutics, Eli Liily, GlaxoSmithKline, Merck, Novartis, Regeneron Pharmaceuticals, Roche, Shire Pharmaceuticals